In this uplifting episode of Bladder Cancer Matters, survivors Sandy Weicher and Danny Gereg share how the Walk to End Bladder Cancer became the turning point they didn't know they needed—a place where strangers become family, hope replaces fear and every mile walked fuels research and critical patient programs.

Sandy describes the moment she arrived at the New York City Walk, surrounded by the skyline and a sea of survivors, caregivers and clinicians, and instantly felt connected to something bigger than her diagnosis. Danny talks about showing up lost and anxious at the Columbus Walk, only to find a community that carried him through his darkest moments and inspired him to fight for his health. Together with host Rick Bangs, they show how the Walk isn't just an event—it's a lifeline, a celebration of resilience, and a reminder that no one faces bladder cancer alone. Their stories will make you smile, tear up, and—most of all—want to join in.

Sign up for a 2026 Walk to End Bladder Cancer.

Three cancers. One relentless survivor. In this unforgettable episode of Bladder Cancer Matters, host Rick Bangs sits down with Lisa Savage, who reveals the shocking twists of her cancer journeys—melanoma caught just in time, a delayed and devastating bladder cancer diagnosis that led to bladder removal and a urostomy bag at age 50, and a third hidden cancer discovered along the way.

With raw honesty and powerful humor, Lisa shares how she survived aggressive chemo, faced a terminal prognosis, fought through fear, and transformed her devastating diagnosis into a mission to mentor others, advocate publicly and live boldly—bag and all. Her story will make you gasp, laugh, tear up and leave inspired to face whatever life throws your way.

In this special 20th-anniversary episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with leading urologic oncologist Dr. Sia Daneshmand to explore a new bladder cancer therapy: Johnson & Johnson's newly FDA-approved INLEXZO™. Dr. Daneshmand—who helped lead its clinical trials—breaks down how this "pretzel-shaped" intravesical delivery system works, why it's showing some of the highest response rates yet for BCG-unresponsive disease and what patients can realistically expect in terms of side effects, treatment schedule, and quality of life. Together, they discuss the future of drug-delivery technology in bladder cancer and why this moment can offer hope to bladder cancer patients.